Dear Sir or Madam,
To avoid any potential confusion regarding the voting rights notification relating to Janus Henderson Group plc (“Janus Henderson”) on August 13, 2026, in relation to its shareholding in Medios AG (“Medios”), we would like to provide you with the following brief clarification.
The 6.4% stake in Medios AG was and continues to be held by Janus Henderson Investors UK Limited. This was duly reported to Medios and published by Medios on October 24, 2025.
As part of an internal restructuring within the Janus Henderson Group, the underlying reporting structure has now changed. In this context, Janus Henderson Group plc and Janus Henderson UK Holdings Limited were required to notify Medios that they no longer control the shares in question. At the same time, the existing notification under the previous reporting entity had to be closed out. This resulted in a number of voting rights notifications, including notifications relating to other companies.
As the 6.4% stake held by Janus Henderson Investors UK Limited in Medios AG had already been reported in October 2025, no new notification was required from that entity. The actual number of shares held by Janus Henderson in Medios AG has not changed.
Medios remains in regular contact with Janus Henderson. The restructuring therefore does not result in any changes to the presentation of Medios’ shareholder structure.
Should you have any questions regarding this matter, please do not hesitate to contact us.
Kind regards,
Investor Relations
Medios AG
Receive e-mail updates on the latest news and the publication of financial reports. This will automatically keep you up to date.
Registration is free of charge and can be revoked at any time.
Katrin Neuffer
Director Investor Relations & Communications
We have been informed of a fake listing of a cosmetic product on the TEMU platform in which Medios is falsely named as the distributor. Unfortunately, such unauthorized product listings are repeatedly observed on unreliable platforms like TEMU.
We would like to clarify: This offer is in no way connected to Medios and is not authorized. Our legal department has been informed.
Please obtain medical products exclusively through authorized and verified sources.
If you have any further questions, please contact: ir@medios.group